GPRC5B Antibody

What is GPRC5B and why is it an important research target?

GPRC5B (G protein-coupled receptor family C group 5 member B) is a retinoic acid-inducible orphan G-protein-coupled receptor belonging to the seven-transmembrane domain family. Despite being an "orphan receptor" with incompletely understood molecular function, GPRC5B has been implicated in multiple significant physiological processes:

• Obesity-associated inflammatory signaling in adipocytes

• Diet-induced insulin resistance

• Beta-cell proliferation and apoptosis regulation

• Macrophage function and inflammatory responses

• Neuropathic pain development after nerve injury

• Glomerular disease processes

GPRC5B is abundantly expressed in the central nervous system and shows region-specific expression patterns across different brain areas, making it particularly valuable for neuroscience research .

How do I select the appropriate anti-GPRC5B antibody for my research?

Selection should be guided by:

• Application requirements: Different validated applications (WB, IF, IHC, FCM, ELISA) require different antibody characteristics

• Species reactivity: Confirm cross-reactivity with your experimental model (human, mouse, rat, etc.)

• Target region specificity: Some antibodies target the N-terminal, C-terminal, or internal regions

• Antibody format: Consider monoclonal vs. polyclonal based on your needs:

  • Monoclonal: Higher specificity, reproducibility

  • Polyclonal: Better signal detection, multiple epitope recognition

Always review validation data and published literature using your antibody of interest .

How can I validate the specificity of my GPRC5B antibody?

A multi-level validation approach is recommended:

• Overexpression system validation: Test antibody on lysates from cells transfected with GPRC5B and related family members (GPRC5A, GPRC5C, GPRC5D) as controls

• Knockout validation: Compare samples from wildtype vs. GPRC5B-knockout models

• Tissue expression profiling: Confirm detection matches known expression patterns (high in brain, variable in other tissues)

• Multiple antibody comparison: Use antibodies targeting different epitopes

• Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding

For example, researchers at University of Rochester validated their custom GPRC5B polyclonal antibody by western blotting against lysates from HEK293 cells transfected with HA-tagged GPRC5A, GPRC5B, GPRC5C, and GPRC5D constructs. Only GPRC5B-transfected samples produced specific bands between 25-50 kDa .

What are the optimal conditions for using anti-GPRC5B antibodies in western blotting?

Optimized western blotting conditions for GPRC5B detection:

• Sample preparation considerations:

  • Use appropriate lysis buffers with protease inhibitors

  • Include phosphatase inhibitors if phospho-specific detection is needed

  • Consider deglycosylation treatments to resolve glycosylated forms

• Technical parameters:

  • Protein loading: 25-50 μg of total protein lysate

  • Gel percentage: 10-12% SDS-PAGE gels recommended

  • Transfer conditions: Wet transfer at 100V for 60-90 minutes

  • Blocking: 5% non-fat milk or BSA in TBST for 1 hour

  • Primary antibody dilution: Typically 1:100-1:500 (antibody-dependent)

  • Secondary antibody: HRP-conjugated, 1:2000-1:5000

  • Detection: Enhanced chemiluminescence

• Expected bands:

  • Native GPRC5B: ~42-45 kDa

  • Glycosylated forms: Additional bands above 37 kDa

  • Deglycosylated form: Lower molecular weight band

Note that deglycosylation assays show that higher-weight bands above 37 kDa collapse to unmodified forms after treatment, confirming glycosylation of GPRC5B in both transfected cells and brain tissue lysates .

Why am I detecting multiple bands with my GPRC5B antibody, and how should I interpret them?

Multiple bands are commonly observed with GPRC5B antibodies and can result from:

• Post-translational modifications:

  • Glycosylation: GPRC5B shows high levels of glycosylation in brain tissue and transfected cells

  • Phosphorylation: Potential modification affecting migration

• Protein processing:

  • Signal peptide cleavage: The predicted molecular weight after signal peptide cleavage is 42.8 kDa

  • Proteolytic processing: Potential generation of fragments

• Splice variants:

  • Alternative splicing resulting in different isoforms

To differentiate between these possibilities:

• Deglycosylation assay: Treatment with glycosidases (PNGase F, Endo H) can confirm glycosylation

• Phosphatase treatment: Removes phosphate groups that may affect migration

• Analysis of different tissue/cell types: Compare expression patterns across samples

• Knockout controls: Essential for confirming band specificity

In one study, researchers observed that bands slightly higher than 37 kDa disappeared after deglycosylation treatment of both GPRC5B-transfected HEK293T cells and brain lysates, confirming glycosylation as the cause of multiple bands .

How do I optimize conditions for immunohistochemical detection of GPRC5B in brain tissue?

Successful detection of GPRC5B in brain tissue requires:

• Tissue preparation considerations:

  • Fixation: Freshly prepared 4% paraformaldehyde recommended

  • Sectioning: 10-20 μm sections for optimal antigen accessibility

  • Antigen retrieval: Citrate buffer (pH 6.0) at 95°C for 15-20 minutes

• Staining protocol optimization:

  • Permeabilization: 0.2-0.3% Triton X-100 in PBS for membrane protein access

  • Blocking: 5-10% normal serum (matching secondary antibody species) with 1% BSA

  • Primary antibody: Start with 1:100-1:200 dilution and optimize

  • Incubation: Overnight at 4°C for best results

  • Secondary antibody: Fluorophore-conjugated or HRP-conjugated (1:500-1:1000)

  • Counterstaining: DAPI for nuclei visualization

• Controls to include:

  • Primary antibody omission

  • Pre-adsorption with immunizing peptide

  • Tissue from GPRC5B knockout animals

Research has shown region-specific GPRC5B expression across brain areas. The olfactory bulb, pons, and cerebellum abundantly express GPRC5B protein, while it's barely detectable in retina lysates .

How can I investigate GPRC5B's physical interactions with other receptors using antibody-based approaches?

GPRC5B has been shown to interact with other receptors, particularly the prostanoid receptor family. To study these interactions:

• Co-immunoprecipitation (Co-IP):

  • Use anti-GPRC5B antibodies to pull down GPRC5B and associated proteins

  • Test for presence of potential interaction partners by western blotting

  • Alternatively, immunoprecipitate partner proteins and probe for GPRC5B

• Proximity ligation assay (PLA):

  • Allows visualization of protein interactions in situ

  • Requires specific antibodies against both interaction partners

  • Signal indicates proteins are within 40 nm of each other

• FRET-based approaches:

  • Förster resonance energy transfer to detect protein-protein interactions

  • Can be antibody-based or using fluorescent protein fusions

• Advanced protein crosslinking:

  • Stabilize transient interactions before immunoprecipitation

  • MS-based identification of interaction partners

Recent research demonstrated that GPRC5B physically interacts with GPCRs of the prostanoid receptor family, particularly the prostaglandin E receptor 2 (EP2), enhancing EP2-mediated signaling. This was confirmed through co-immunoprecipitation experiments and FRET analysis in HEK cells .

How can antibodies help elucidate the subcellular localization and trafficking of GPRC5B?

Understanding GPRC5B's subcellular distribution requires:

• Subcellular fractionation combined with western blotting:

  • Separate cellular compartments (membrane, cytosol, nuclear)

  • Probe fractions with anti-GPRC5B antibodies

  • Include markers for different compartments as controls

• Immunofluorescence microscopy:

  • Co-staining with compartment markers:

    • Plasma membrane: Na+/K+ ATPase

    • Endoplasmic reticulum: Calnexin

    • Golgi: GM130

    • Endosomes: EEA1, Rab5, Rab7

    • Post-synaptic density: PSD-95

• Live-cell imaging of trafficking:

  • Antibody labeling of surface GPRC5B

  • Tracking internalization and recycling

Research has shown that GPRC5B localizes to both intracellular compartments and the post-synaptic density (PSD) in neurons, as demonstrated by biochemical fractionation assays . Additionally, immunofluorescence studies of HEK cells co-transfected with GPRC5B and EP2 receptor showed overlapping intracellular distribution .

How is GPRC5B antibody research contributing to understanding disease mechanisms?

GPRC5B antibodies have enabled critical discoveries in multiple disease contexts:

• Neuropathic pain:

  • GPRC5B expression decreases in the ipsilateral dorsal horn after spinal nerve ligation

  • This downregulation occurs specifically in NeuN-positive neurons

  • Changes in GPRC5B levels may affect microglial activation in neuropathic pain models

• Renal diseases:

  • GPRC5B is upregulated in common human glomerular diseases:

    • IgA nephropathy

    • Lupus nephritis

    • Diabetic nephropathy

  • Antibody-based detection shows GPRC5B modulates inflammatory responses in glomerular diseases

• Inflammation and immunity:

  • GPRC5B regulates macrophage function through interaction with prostaglandin receptors

  • Knockout studies using GPRC5B antibodies for validation show enhanced migration and phagocytosis in GPRC5B-deficient macrophages

• Multiple myeloma:

  • GPRC5D (related family member) is a target for antibody therapies in multiple myeloma

  • Structural studies of antibody binding inform therapeutic development

These findings highlight how antibody-based detection of GPRC5B expression and localization contributes to understanding diverse pathological mechanisms.

What are the best approaches for using GPRC5B antibodies in functional studies of GPRC5B signaling?

To investigate GPRC5B signaling mechanisms:

• Downstream signaling pathway analysis:

  • Use phospho-specific antibodies to detect activation of downstream effectors

  • Monitor changes after perturbation of GPRC5B expression

• Knockdown/knockout validation approaches:

  • siRNA or CRISPR-based knockout of GPRC5B

  • Compare signaling responses with and without GPRC5B

  • Use antibodies to confirm knockdown/knockout efficiency

• Receptor dimerization and complexing:

  • Co-immunoprecipitation with other receptors

  • Native PAGE with antibody detection

  • Chemical crosslinking followed by immunoprecipitation

• Mutational analysis:

  • Generate GPRC5B mutants affecting key residues

  • Use antibodies to verify expression and localization

  • Assess effects on signaling and protein interactions

Recent research has identified crucial residues for GPRC5B's interaction with the EP2 receptor through a combination of in silico modeling, mutagenesis, and functional assays. Specifically, mutation of residues F97A, L101A, and L104A disrupted the interaction between GPRC5B and EP2, preventing GPRC5B-mediated facilitation of EP2 signaling .

How can novel antibody technologies enhance GPRC5B research?

Emerging antibody technologies with potential for GPRC5B research:

• Single-domain antibodies (nanobodies):

  • Smaller size enables access to cryptic epitopes

  • Can be used intracellularly as "intrabodies"

  • Potential for capturing specific conformational states of GPRC5B

• Antibody-based biosensors:

  • FRET-based conformational sensors

  • Detection of ligand binding and receptor activation

  • Real-time monitoring of GPRC5B activity

• Antibody fragments and bispecific formats:

  • scFv, Fab, and bispecific formats for specialized applications

  • Enhanced tissue penetration for in vivo imaging

  • Targeting multiple epitopes simultaneously

• Selective antibody-based protein degradation:

  • Proteolysis-targeting chimeras (PROTACs) incorporating GPRC5B antibodies

  • Targeted degradation of GPRC5B for functional studies

• Cryo-EM with antibody fragments:

  • Using antibody fragments (Fab, scFv) as fiducial markers

  • Stabilizing specific conformations for structural studies

  • Similar to approaches used with GPRC5D and scFv complexes

What are the key considerations for developing antibodies to study GPRC5B in human disease tissue samples?

For clinical and translational applications:

• Epitope selection considerations:

  • Target conserved regions between model organisms and humans

  • Avoid regions with known disease-associated mutations

  • Consider regions not affected by post-translational modifications

• Validation in relevant disease models:

  • Test in both animal models and human patient samples

  • Compare with established markers of disease progression

  • Include appropriate disease and normal tissue controls

• Technical optimization for clinical samples:

  • Compatibility with standard fixation protocols (formalin, paraffin)

  • Robust performance with antigen retrieval methods

  • Quantifiable signals for comparative analysis

• Multiplexed detection approaches:

  • Co-staining with cell type and activation markers

  • Spatial profiling of GPRC5B with other disease markers

  • Digital pathology and automated quantification

Antibody-based studies have shown that GPRC5B expression changes are associated with various pathological conditions, including downregulation in neuropathic pain models and upregulation in glomerular diseases , highlighting the importance of reliable antibodies for clinical tissue analysis.